Leadership Overview
Probiotec has 4 executives leading key functions including strategy, finance, operations, and human resources.
Driven by a commitment to innovation and quality, Probiotec excels in manufacturing, marketing, and distributing pharmaceuticals and complementary medicines, serving blue-chip manufacturers and FMCG clients with advanced facilities and experienced personnel.
Driven by a commitment to innovation and quality, Probiotec excels in manufacturing, marketing, and distributing pharmaceuticals and complementary medicines, serving blue-chip manufacturers and FMCG clients with advanced facilities and experienced personnel.
Leadership Roles at Probiotec
Westley Stringer - Chief Executive Officer
Westley Stringer, the Chief Executive Officer at Probiotec, directs the overarching corporate strategy and market positioning for the Australian-based pharmaceutical and complementary medicines company. Stringer guides Probiotec's expansion in contract manufacturing and packaging services, ensuring alignment with the company's commitment to innovation and quality across its diverse client base, which includes food, personal care, and pharmaceutical sectors. This leadership role involves overseeing the strategic direction of subsidiaries like Probiotec Pharma and Probiotec Multipack, ensuring their specialized services in manufacturing and secondary packing for consumer goods meet stringent industry standards. By focusing on high-quality solutions, Westley Stringer drives the company's engagement with blue-chip manufacturers and FMCG clients, leveraging advanced facilities and experienced personnel to maintain Probiotec's competitive edge in the market. The Chief Executive Officer's vision is central to Probiotec's continued growth and its reputation for excellence in the Australian market.
Jared Stringer - Chief Financial Officer
Jared Stringer, the Chief Financial Officer at Probiotec, manages all financial operations and fiscal strategy for the Melbourne-based manufacturer and distributor. Stringer oversees financial planning, budgeting, and reporting, ensuring robust fiscal health and supporting Probiotec's growth initiatives in prescription and over-the-counter pharmaceuticals and complementary medicines. This executive ensures capital allocation aligns with strategic objectives, particularly for contract manufacturing and packaging services catering to food, personal care, and pharmaceutical industries. Jared Stringer's responsibilities include managing investor relations and securing funding to support the company's advanced facilities and experienced personnel. The Chief Financial Officer plays a critical part in evaluating new market opportunities and acquisitions, ensuring financial viability and maximizing shareholder value. Stringer's financial acumen is essential for Probiotec's sustained success and its ability to serve blue-chip manufacturers and FMCG clients effectively.
Julie McIntosh - Chief Operating Officer
Julie McIntosh, the Chief Operating Officer at Probiotec, directs the operational execution and efficiency across the company's manufacturing, marketing, and distribution functions. McIntosh oversees the day-to-day activities of Probiotec's facilities in Laverton North, Victoria, ensuring the seamless delivery of prescription and over-the-counter pharmaceuticals and complementary medicines. This leadership role involves optimizing production processes for contract manufacturing and packaging services, supporting diverse industries such as food, personal care, and pharmaceuticals. Julie McIntosh ensures that Probiotec's subsidiaries, including Probiotec Pharma and Probiotec Multipack, operate at peak performance, providing specialized manufacturing and secondary packing for a variety of consumer goods. The Chief Operating Officer focuses on maintaining high standards of quality and innovation, leveraging advanced facilities and experienced personnel to meet the demands of blue-chip manufacturers and FMCG clients. McIntosh's operational oversight is fundamental to Probiotec's reputation for reliability and excellence.
Annalinde Nickisch - Chief People Officer
Annalinde Nickisch, the Chief People Officer at Probiotec, leads human capital strategy and organizational development for the Australian pharmaceutical and complementary medicines company. Nickisch is responsible for attracting, retaining, and developing the skilled workforce essential for Probiotec's operations, including its contract manufacturing and packaging services. This executive ensures a robust talent pipeline to support advanced facilities and experienced personnel across all departments, from manufacturing to distribution. Annalinde Nickisch cultivates a company culture that fosters innovation and quality, aligning with Probiotec's commitment to serving blue-chip manufacturers and FMCG clients. The Chief People Officer oversees employee relations, compensation, benefits, and performance management, ensuring compliance and promoting a productive work environment. Nickisch's strategic approach to human resources is vital for maintaining Probiotec's operational excellence and its capacity to deliver high-quality solutions.
Explore Leadership Teams in Manufacturing
Unither Pharmaceuticals is a global contract development and manufacturing organization (CDMO) specializing in the production of single-dose liquid pharmaceuticals and sterile unit-dose formats for the pharmaceutical and consumer healthcare industries. The company is recognized as a world leader in blow-fill-seal technology, an advanced aseptic manufacturing process that forms, fills, and seals plastic containers in a continuous automated operation, ensuring high levels of sterility and product integrity. Unither's expertise encompasses the development and manufacturing of various liquid dosage forms including oral solutions, suspensions, nasal sprays, eye drops, and other sterile and non-sterile pharmaceutical products delivered in innovative single-dose formats. The company serves a diverse client base of pharmaceutical companies, biotechnology firms, and consumer health brands, providing comprehensive services from formulation development and clinical trial manufacturing to commercial-scale production and packaging. With manufacturing facilities strategically located across multiple continents including Europe and North America, Unither maintains strict quality standards and regulatory compliance with international pharmaceutical guidelines including FDA and EMA requirements. The company emphasizes innovation in drug delivery systems, patient convenience, and sustainability while helping clients bring their pharmaceutical products to market efficiently through its specialized manufacturing capabilities and technical expertise in unit-dose liquid formulations.
Company Leadership HH
JK
MC
MB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Company Leadership
CE
ST
Pfizer is a biopharmaceutical company that researches, develops, manufactures, and markets medicines and vaccines across multiple therapeutic areas. The company focuses on areas such as oncology, internal medicine, inflammation and immunology, and vaccines to help prevent, treat, and manage disease worldwide.
Company Leadership BS
JC
NA
SM
Founded in 1947 and headquartered in Mumbai, Indoco Remedies Limited is a fully integrated, research-oriented pharma company. Indoco specializes in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).
Company Leadership BD
PG
PA
Frequently Asked Questions Regarding Probiotec Top Executives and Leadership Team
